Avastin and Taxotere for Esophagogastric Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-08-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin) and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

NCT00442507

Esophageal Neoplasms Esophageal Diseases

TERMINATED PHASE2

Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

NCT00570531

Loco-regional Esophageal Cancer

TERMINATED PHASE2

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

NCT00636298

Esophageal Carcinoma

WITHDRAWN PHASE2

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

NCT00318903

Esophageal Cancer Cancer of the Esophagus Esophagus Cancer +2 more

COMPLETED PHASE2

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

NCT02358863

Esophageal Cancer Gastric Cancer

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bevacizumab will be administered intravenously in an outpatient clinic once a week, every other week. Docetaxel will also be administered intravenously in the outpatient clinic once a week for three out of four weeks. Blood tests and vital signs will be performed weekly.

After the first eight weeks of therapy a CT scan will be performed to determine and assess the progress of the disease. If therapy is continued, radiological procedures will be performed at week 16 and every 8 weeks thereafter.

Treatment will be given for a minimum of 8 weeks, as long as the patient does not experience unacceptable side effects. Chemotherapy will continue for a year and a half as long as the cancer is responding and there are no unacceptable side effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Docetaxel

Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half

Intervention Type DRUG

Bevacizumab

Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AvaTax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed, unresectable or metastatic stage IV esophageal or gastric carcinoma
* Measurable disease greater than or equal to 1cm by spiral computed tomography (CT) scan or greater than or equal to 2cm by other radiographic technique
* ECOG performance status 0-2
* One prior chemotherapy for metastatic disease permitted
* White blood cell count greater than or equal to 3,000/mm
* Absolute neutrophil count greater than or equal to 1,500/mm3
* Platelet count greater than or equal to 100,000/mm3
* Hemoglobin greater than or equal to 8.0g/dl
* Creatinine less than 2.0mg/dL
* Total bilirubin less than 1.9mg/dL

Exclusion Criteria

* Pregnant or lactating women
* History or evidence of central nervous system (CNS) disease
* Other active malignancies other than non-melanoma skin cancer or in-situ cervical cancer
* History of severe hypersensitivity to docetaxel, bevacizumab or drugs formulated with polysorbate 80.
* Current, recent or planned treatment with standard chemotherapy, radiation therapy or another experimental therapy.
* History of other disease or metabolic dysfunction.
* Serious, non-healing wound, ulcer, or bone fracture.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No